Sign in

CIK 0001652130 · Large accelerated filer

Intellia Therapeutics, Inc.

Sign in to watch
Ticker
NTLA
Exchange
Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
364785571
Phone
857-285-6200
Business address
400 TECHNOLOGY SQUARE, SUITE 100, CAMBRIDGE, MA
  1. 4 Grant or award EVP, Chief Business Officer acquired 23,558 shares (grant or award)
  2. 4 Grant or award EVP, Chief Financial Officer acquired 27,484 shares (grant or award)
  3. 4 Grant or award President and CEO acquired 91,036 shares (grant or award)
  4. 4 Grant or award EVP, Chief Medical Officer acquired 30,674 shares (grant or award)
  5. 4 Grant or award EVP, Chief Scientific Officer acquired 29,938 shares (grant or award)
  6. 4 Grant or award EVP, Chief Technical Officer acquired 30,673 shares (grant or award)
  7. 4 Open-market sale EVP, General Counsel sold 1,088 shares at $43.88 ($47,741)
  8. 8-K Event Other events
  9. S-8 Other Securities Offered to Employees in Benefit Plans
  10. 10-K Report Annual Report
  11. 8-K Event Results of operations
  12. SC 13G/A Stake Amended Statement of Ownership
  13. SC 13G/A Stake Amended Statement of Ownership
  14. SC 13G/A Stake Amended Statement of Ownership
  15. SC 13G Stake Amended Statement of Ownership
  16. 4 Open-market sale EVP, Chief Scientific Officer sold 4,838 shares at an average $37.82 ($182,982)
  17. 4 Open-market sale President and CEO sold 6,673 shares at $37.21 ($248,302)
  18. 4 Open-market sale EVP, Chief Business Officer sold 1,812 shares at $37.21 ($67,425)
  19. 4 Open-market sale EVP, Chief Medical Officer sold 2,574 shares at $37.21 ($95,779)
  20. 4 Open-market sale EVP, Chief Financial Officer sold 2,427 shares at $37.21 ($90,309)

Page 13 of 37 · 725 filings